Northwest Biotherapeutics, Inc  

(Public, NASDAQ:NWBO)   Watch this stock  
7.67
-0.03 (-0.39%)
Sep 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.52 - 7.93
52 week 3.79 - 12.55
Open 7.53
Vol / Avg. 412,227.00/798,905.00
Mkt cap 601.91M
P/E     -
Div/yield     -
EPS -2.54
Shares 78.17M
Beta 2.14
Inst. own 33%
Sep 9, 2015
Northwest Biotherapeutics Inc at Rodman & Renshaw Global Investment Conference - 2:10PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -17095.91% -9328.34%
Operating margin -9937.08% -6925.31%
EBITD margin - -6955.43%
Return on average assets -471.78% -360.54%
Return on average equity - -
Employees 12 -
CDP Score - -

Address

Suite 800, 4800 Montgomery Lane
BETHESDA, MD 20814
United States - Map
+1-240-4979024 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patient's tumor. DCVax product lines are made from the patient's own dendritic cells, which are freshly isolated, and matured and activated. The Company's DCVax product lines include DCVax-L, DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen, PSMA (Prostate Specific Membrane Antigen), which is found on all late stage prostate cancers.

Officers and directors

Linda F. Powers Chairperson of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Leslie J. Goldman Senior Vice President - Business Development
Age: 70
Bio & Compensation  - Reuters
Anthony E. Maida Ph.D. Senior Vice President - Clinical Research
Age: 61
Bio & Compensation  - Reuters
Marnix L. Bosch Ph.D Chief Technical Officer
Age: 55
Bio & Compensation  - Reuters
Alton L. Boynton Ph.D. Chief Scientific Officer, Director
Age: 71
Bio & Compensation  - Reuters
Robert A. Farmer Independent Director
Age: 75
Bio & Compensation  - Reuters
Jerry J. Jasinowski Independent Director
Age: 72
Bio & Compensation  - Reuters
Navid Malik Independent Director
Age: 46
Bio & Compensation  - Reuters